Acronym:
ANZUP 1603
ACTRN/NCT /ethics:
Scientific title:
Summary of trial and patient characteristics
| Cancer Type | Prostate | ||
|---|---|---|---|
| Trial Type | Treatment | ||
| Phase | Phase II | Tumour Stream | Prostate |
| Age Range | 18 years and older | Cancer Stage | Metastatic or Widespread |
| Sex | Male | Anticipated Start Date | |
| Molecular Target | Anticipated End Date | ||
| Cancer Type | Prostate |
|---|---|
| Trial Type | Treatment |
| Phase | Phase II |
| Age Range | 18 years and older |
| Sex | Male |
| Molecular Target | |
| Tumour Stream | Prostate |
| Cancer Stage | Metastatic or Widespread |
| Anticipated Start Date | |
| Anticipated End Date |
Trial Summary
TheraP: A randomised phase II trial of 177 LuPSMA617 theranostic versus cabazitaxel in men with progressive metastatic castration resistant prostate cancer.
Lay Summary
Sponsor / Cooperative group
ANZUP
Participating Hospitals
| Hospital | Clinical Trial Coordinator | Phone | Principal Investigator | Recruitment Status | |
|---|---|---|---|---|---|
| Royal Adelaide Hospital | Anne Milton | anne.milton@sa.gov.au | 08 7074 2342 | Tan | Recruiting |